Tonix Pharmaceuticals to Present at BTIG Infectious Disease Day 2026

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial-stage biotechnology company, announced that members of its management team will participate in one-on-one meetings at BTIG’s Infectious Disease Day 2026, which will be held virtually on June 16, 2026. Seth Lederman, M.D., president and chief executive officer of Tonix Pharmaceuticals, will represent the company during the event.

The participation at BTIG’s Infectious Disease Day underscores Tonix’s commitment to advancing its immunology pipeline. Among the company’s key programs is TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, which addresses a significant unmet medical need. Lyme disease affects hundreds of thousands of people annually in the United States, and current preventive options are limited. Tonix is also developing TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection, which could address a substantial market in transplantation.

Tonix’s immunology efforts complement its central nervous system (CNS) franchise, which includes the recently approved flagship medicine TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg) for fibromyalgia. TONMYA is the first new treatment for fibromyalgia in over 15 years, and the company is exploring its potential in major depressive disorder and acute stress disorder through Phase 2 clinical trials. Additionally, Tonix’s CNS portfolio includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease with no approved therapies.

The company’s CNS commercial infrastructure supports its marketed products, including Zembrace SymTouch and Tosymra for acute migraine. By participating in BTIG Infectious Disease Day, Tonix aims to highlight the breadth of its pipeline to investors and industry experts. The virtual format of the event allows for efficient engagement with a wide audience.

Tonix Pharmaceuticals is a fully integrated commercial-stage company with a focus on CNS and immunology treatments in areas of high unmet need. The company’s participation in this event provides an opportunity to discuss its immunology candidates and their potential impact. For more information about Tonix, visit the company’s newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/38XUG.

Note to investors: Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.